> Detailanzeige
Ekanem, Emmanuel;
Neuzil, Petr;
Reichlin, Tobias;
Kautzner, Joseph;
van der Voort, Pepijn;
Jais, Pierre;
Chierchia, Gian-Battista;
Bulava, Alan;
Blaauw, Yuri;
Skala, Tomas;
Fiala, Martin;
Duytschaever, Mattias;
Szeplaki, Gabor;
Schmidt, Boris;
Massoullie, Grégoire;
Neven, Kars;
Thomas, Olivier;
Vijgen, Johan;
Gandjbakhch, Estelle;
Scherr, Daniel;
Johannessen, Arne;
Keane, David;
Boveda, Serge;
Maury, Philippe;
[...]
Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
Teilen
Literatur-
verwaltung
Direktlink
Zur
Merkliste
Lösche von
Merkliste
Per Email teilen
Auf Twitter teilen
Auf Facebook teilen
Per Whatsapp teilen
- Medientyp: E-Artikel
- Titel: Safety of pulsed field ablation in more than 17,000 patients with atrial fibrillation in the MANIFEST-17K study
- Beteiligte: Ekanem, Emmanuel; Neuzil, Petr; Reichlin, Tobias; Kautzner, Joseph; van der Voort, Pepijn; Jais, Pierre; Chierchia, Gian-Battista; Bulava, Alan; Blaauw, Yuri; Skala, Tomas; Fiala, Martin; Duytschaever, Mattias; Szeplaki, Gabor; Schmidt, Boris; Massoullie, Grégoire; Neven, Kars; Thomas, Olivier; Vijgen, Johan; Gandjbakhch, Estelle; Scherr, Daniel; Johannessen, Arne; Keane, David; Boveda, Serge; Maury, Philippe; [...]
-
Erschienen:
Springer Science and Business Media LLC, 2024
- Erschienen in: Nature Medicine, 30 (2024) 7, Seite 2020-2029
- Sprache: Englisch
- DOI: 10.1038/s41591-024-03114-3
- ISSN: 1078-8956; 1546-170X
- Entstehung:
- Anmerkungen:
- Beschreibung: AbstractPulsed field ablation (PFA) is an emerging technology for the treatment of atrial fibrillation (AF), for which pre-clinical and early-stage clinical data are suggestive of some degree of preferentiality to myocardial tissue ablation without damage to adjacent structures. Here in the MANIFEST-17K study we assessed the safety of PFA by studying the post-approval use of this treatment modality. Of the 116 centers performing post-approval PFA with a pentaspline catheter, data were received from 106 centers (91.4% participation) regarding 17,642 patients undergoing PFA (mean age 64, 34.7% female, 57.8% paroxysmal AF and 35.2% persistent AF). No esophageal complications, pulmonary vein stenosis or persistent phrenic palsy was reported (transient palsy was reported in 0.06% of patients; 11 of 17,642). Major complications, reported for ~1% of patients (173 of 17,642), were pericardial tamponade (0.36%; 63 of 17,642) and vascular events (0.30%; 53 of 17,642). Stroke was rare (0.12%; 22 of 17,642) and death was even rarer (0.03%; 5 of 17,642). Unexpected complications of PFA were coronary arterial spasm in 0.14% of patients (25 of 17,642) and hemolysis-related acute renal failure necessitating hemodialysis in 0.03% of patients (5 of 17,642). Taken together, these data indicate that PFA demonstrates a favorable safety profile by avoiding much of the collateral damage seen with conventional thermal ablation. PFA has the potential to be transformative for the management of patients with AF.